NO20075287L - Kombinasjon av antikolinergika og leukotnen-reseptorantagonister for behandling av andedrettslidelser - Google Patents

Kombinasjon av antikolinergika og leukotnen-reseptorantagonister for behandling av andedrettslidelser

Info

Publication number
NO20075287L
NO20075287L NO20075287A NO20075287A NO20075287L NO 20075287 L NO20075287 L NO 20075287L NO 20075287 A NO20075287 A NO 20075287A NO 20075287 A NO20075287 A NO 20075287A NO 20075287 L NO20075287 L NO 20075287L
Authority
NO
Norway
Prior art keywords
combination
receptor antagonists
anticholinergics
treatment
leukotnene
Prior art date
Application number
NO20075287A
Other languages
English (en)
Other versions
NO340405B1 (no
Inventor
Istvan Szelenyi
Joachim Maus
Peter Juergen Cnota
Ursula Petzold
Torsten Hoffmann
Mario Weingart
Beatrix Fyrnys
Ullrich Munzel
Original Assignee
Meda Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co Kg filed Critical Meda Pharma Gmbh & Co Kg
Publication of NO20075287L publication Critical patent/NO20075287L/no
Publication of NO340405B1 publication Critical patent/NO340405B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelse vedrører en kombinasjon omfattende topiske (inhalerte) antikolinergika og inhalerte eller orale leukotrien (LT) reseptorantagonister (BLT og CysLT reseptorantagonister) for behandling av luftveissykdommer inklusive allergisk rinitt, bronkialastma og kronisk obstruktiv lungesykdom (kols). Oppfinnelsen omfatter videre fremlegging av denne kombinasjon i en lokalt påført (inhalert) sammensetning og anvendelse i en inhaleringsinnretning som for eksempel "Novolizer(r)".
NO20075287A 2005-03-16 2007-10-16 Kombinasjon av antikolinergika og leukotrien-reseptorantagonister for behandling av luftveissykdommer NO340405B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66191805P 2005-03-16 2005-03-16
PCT/EP2006/002247 WO2006097250A1 (en) 2005-03-16 2006-03-10 The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases

Publications (2)

Publication Number Publication Date
NO20075287L true NO20075287L (no) 2007-12-05
NO340405B1 NO340405B1 (no) 2017-04-18

Family

ID=36570797

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075287A NO340405B1 (no) 2005-03-16 2007-10-16 Kombinasjon av antikolinergika og leukotrien-reseptorantagonister for behandling av luftveissykdommer

Country Status (19)

Country Link
US (1) US8268864B2 (no)
EP (1) EP1863476B1 (no)
JP (1) JP4991693B2 (no)
CN (1) CN101128196B (no)
AU (1) AU2006224842B2 (no)
CA (1) CA2595791C (no)
CY (1) CY1117571T1 (no)
DK (1) DK1863476T3 (no)
ES (1) ES2570332T3 (no)
HK (1) HK1114013A1 (no)
HR (1) HRP20160373T1 (no)
HU (1) HUE027076T2 (no)
MX (1) MX2007011273A (no)
NO (1) NO340405B1 (no)
NZ (1) NZ560206A (no)
PL (1) PL1863476T3 (no)
RU (1) RU2420285C2 (no)
SI (1) SI1863476T1 (no)
WO (1) WO2006097250A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
DK1660492T3 (da) * 2003-07-28 2008-11-03 Janssen Pharmaceutica Nv Benzimidazol-, benzthiazol- og benzoxazolderivater og deres anvendelse som LTA4H-modulatorer
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
EP2200550B1 (en) 2007-10-18 2018-04-18 Rose U, LLC Topical glycopyrrolate formulations
EP2211863A4 (en) * 2007-10-25 2012-07-25 Merck Canada Inc COMBINATION THERAPY
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
US9378456B2 (en) * 2012-11-19 2016-06-28 Microsoft Technology Licensing, Llc Task completion
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
EP3842419B1 (en) 2013-02-28 2024-04-03 Journey Medical Corporation Method of making threo glycopyrrolate tosylate
EP2968359B1 (en) 2013-03-12 2021-01-20 Celltaxis, LLC Methods of inhibiting leukotriene a4 hydrolase
KR20150127245A (ko) 2013-03-14 2015-11-16 켈탁시스, 인코퍼레이티드 류코트라이엔 a4 가수분해효소의 저해제
JP2017505809A (ja) * 2014-01-10 2017-02-23 ディグニティ サイエンシス リミテッド １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法
WO2019232306A1 (en) 2018-05-31 2019-12-05 Celtaxsys, Inc. Method of reducing pulmonary exacerbations in respiratory disease patients
TW202042813A (zh) * 2019-01-10 2020-12-01 大陸商江陰貝瑞森製藥有限公司 含有白三烯受體拮抗劑的新穎調配物
IL295262A (en) * 2020-02-03 2022-10-01 Taro Pharma Ind Montelukast transdermal formulation
CN115792229B (zh) * 2022-01-28 2024-06-18 华中科技大学同济医学院附属同济医院 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0435038A (ja) * 1990-05-31 1992-02-05 Oki Electric Ind Co Ltd 半導体素子及びその製造方法
CA2165192C (en) 1993-07-02 2001-04-24 Hermann Amschler Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
EP0932401A1 (en) 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
PL195520B1 (pl) * 1996-11-11 2007-09-28 Meda Pharma Gmbh & Co Kg Enancjomerycznie czyste estry, farmaceutycznie dopuszczalna sól, sposób wytwarzania, środek leczniczy i zastosowanie enancjomerycznie czystych estrów
AU6878098A (en) * 1997-04-30 1998-11-24 Warner-Lambert Company Topical nasal antiinflammatory compositions
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6402285B1 (en) * 1998-05-29 2002-06-11 Citizen Watch Co., Ltd. Method of subjecting ink jet printer to preuse treatment
WO2000007567A1 (de) 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
PT1131059E (pt) 1998-11-13 2003-07-31 Jago Res Ag Po seco para inalacao
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
AU2002221741B2 (en) * 2000-10-31 2007-04-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative solution formulation containing a tiotropium salt
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0029903D0 (en) 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
PL207377B1 (pl) 2001-03-30 2010-12-31 Jagotec Ag Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
ATE347361T1 (de) 2001-05-25 2006-12-15 Boehringer Ingelheim Pharma Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
AP2003002909A0 (en) 2001-05-25 2003-12-31 Pfizer A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
US20040053902A1 (en) * 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
SI1610787T1 (sl) 2003-03-28 2008-06-30 Nycomed Gmbh Sinergistična kombinacija, ki obsega roflumilastin antiholinergično sredstvo, izbrano izmed tiotropijevih soli, za zdravljenje respiratornih bolezni
JPWO2005055999A1 (ja) 2003-12-08 2007-07-05 日本新薬株式会社 抗コリン作用剤
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
SI1863476T1 (sl) 2016-05-31
HRP20160373T1 (hr) 2016-05-06
HK1114013A1 (en) 2008-10-24
JP2008533072A (ja) 2008-08-21
ES2570332T3 (es) 2016-05-17
CY1117571T1 (el) 2017-04-26
US20060211729A1 (en) 2006-09-21
NZ560206A (en) 2009-09-25
AU2006224842A1 (en) 2006-09-21
CA2595791A1 (en) 2006-09-21
AU2006224842B2 (en) 2011-09-29
CN101128196B (zh) 2013-01-02
DK1863476T3 (en) 2016-05-17
CN101128196A (zh) 2008-02-20
RU2420285C2 (ru) 2011-06-10
JP4991693B2 (ja) 2012-08-01
HUE027076T2 (en) 2016-08-29
EP1863476A1 (en) 2007-12-12
EP1863476B1 (en) 2016-02-03
PL1863476T3 (pl) 2016-07-29
CA2595791C (en) 2013-10-08
MX2007011273A (es) 2007-11-08
US8268864B2 (en) 2012-09-18
NO340405B1 (no) 2017-04-18
WO2006097250A1 (en) 2006-09-21
RU2007138270A (ru) 2009-04-27

Similar Documents

Publication Publication Date Title
NO20075287L (no) Kombinasjon av antikolinergika og leukotnen-reseptorantagonister for behandling av andedrettslidelser
ATE541570T1 (de) Kombination von anticholinergika und hemmern von phosphodiesterase typ 4 zur behandlung von atemwegserkrankungen
CY1108978T1 (el) Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες
MXPA02011311A (es) Composicion novedosa.
WO2005074900A3 (en) NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
SE0200356D0 (sv) Novel use
MEP30108A (en) Formoterol superfine formulation
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
BRPI0606283A2 (pt) formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula
CY1110519T1 (el) Συνδυασμος r,r-γλυκοπυρρολικου, ρολιπραμης και βουδεσονιδης για την αντιμετωπιση φλεγμονωδων νοσων
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
ME00349B (me) Novi kristalni anhidrat sa antiholinergij skim dejstvom
NO20083683L (no) Nebulisatorformulering
WO2011093819A3 (en) New pharmaceutical combination comprising tiotropium
EA200500328A1 (ru) Композиция и лекарственное средство для лечения респираторных заболеваний, аллергических заболеваний, астмы и/или хронических обструктивных заболеваний легких и способ получения лекарственного средства
SE9900833D0 (sv) Novel combination
HRP20050468A2 (en) Pulverulent formulation for inhalation containing tiotropium
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
MX2010012019A (es) Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2.
EP2323656A4 (en) PHARMACEUTICAL PRODUCT USING A MUSCARIN RECEPTOR ANTAGONIST AND A BETA-2 ADRENOZEPTORAGONIST
SE9900834D0 (sv) Novel combination
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
EA201070917A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты
MXPA04007294A (es) Composicion para inhalacion.
ATE475409T1 (de) Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees